Compositions comprising enzyme-cleavable oxycodone prodrug
US8497237B2 · kind B2 · utility
22Cited by
8References
31Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 9, 2012 |
| Grant date | Jul 30, 2013 |
| Priority date | — |
| Expiry date | Jan 9, 2032 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/976
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The embodiments provide Compound KC-7, N-1-[(S)-2-(oxycodone-6-enol-carbonyl-methyl-amino)-2-carbonyl-sarcosine-ethyl amine]-arginine-glycine-acetate, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug, Compound KC-7, that provides controlled release of oxycodone. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of oxycodone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.